A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 700 shares of HRMY stock, worth $23,842. This represents 0.0% of its overall portfolio holdings.

Number of Shares
700
Previous 2,200 68.18%
Holding current value
$23,842
Previous $66,000 59.09%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.0 - $39.95 $15.9 Million - $21.2 Million
-529,642 Reduced 77.4%
154,676 $6.18 Million
Q2 2024

Aug 14, 2024

BUY
$28.81 - $33.01 $2.96 Million - $3.39 Million
102,698 Added 17.66%
684,318 $20.6 Million
Q1 2024

May 15, 2024

BUY
$29.93 - $35.06 $15.1 Million - $17.6 Million
502,887 Added 638.72%
581,620 $19.5 Million
Q4 2023

Feb 14, 2024

SELL
$19.2 - $33.78 $3.14 Million - $5.52 Million
-163,347 Reduced 67.48%
78,733 $2.54 Million
Q3 2023

Nov 14, 2023

SELL
$31.89 - $39.03 $17.8 Million - $21.8 Million
-558,780 Reduced 69.77%
242,080 $7.93 Million
Q2 2023

Aug 14, 2023

BUY
$30.5 - $37.4 $8.21 Million - $10.1 Million
269,053 Added 50.59%
800,860 $28.2 Million
Q1 2023

May 15, 2023

BUY
$30.8 - $53.92 $12.2 Million - $21.3 Million
395,854 Added 291.17%
531,807 $17.4 Million
Q4 2022

Feb 14, 2023

SELL
$45.4 - $60.91 $374,550 - $502,507
-8,250 Reduced 5.72%
135,953 $7.49 Million
Q3 2022

Nov 14, 2022

BUY
$42.06 - $55.45 $2.98 Million - $3.92 Million
70,740 Added 96.29%
144,203 $6.39 Million
Q2 2022

Aug 15, 2022

SELL
$33.54 - $52.15 $3.19 Million - $4.96 Million
-95,016 Reduced 56.4%
73,463 $3.58 Million
Q1 2022

May 16, 2022

BUY
$33.14 - $51.13 $2.59 Million - $3.99 Million
78,048 Added 86.31%
168,479 $8.2 Million
Q4 2021

Feb 14, 2022

BUY
$34.09 - $43.91 $1.68 Million - $2.17 Million
49,384 Added 120.31%
90,431 $3.86 Million
Q3 2021

Nov 15, 2021

SELL
$25.68 - $38.61 $95,632 - $143,783
-3,724 Reduced 8.32%
41,047 $1.57 Million
Q2 2021

Aug 16, 2021

SELL
$25.96 - $33.44 $155,967 - $200,907
-6,008 Reduced 11.83%
44,771 $1.26 Million
Q1 2021

May 17, 2021

BUY
$27.56 - $40.37 $639,281 - $936,422
23,196 Added 84.1%
50,779 $1.68 Million
Q4 2020

Feb 16, 2021

SELL
$31.74 - $51.34 $6.09 Million - $9.86 Million
-192,010 Reduced 87.44%
27,583 $997,000
Q3 2020

Nov 16, 2020

BUY
$30.96 - $44.39 $6.8 Million - $9.75 Million
219,593 New
219,593 $7.45 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.